From Yahoo! Finance: The Multidisciplinary Association for Psychedelic Studies (MAPS) has passed a major hurdle on the path to getting MDMA approved for medical use. The psychedelic has been granted the designation of “breakthrough therapy,” meaning that it will move toward the final phase of medical trials that could one day lead to prescription use of the drug to treat PTSD.
“Psychedelic-based treatments ‘offer an opportunity to dig down and get to the heart of the problems that drive long term mental illness in a much more effective way than our current model, which is take daily medications to mask the symptoms and stay just-about level without digging down,’ Sessa said.
It’s a source of hope to many people struck by conditions like anxiety and depression — especially those who haven’t responded to traditional treatments like talk therapy and antidepressants.”
